目的：探究人衰老关键蛋白1（Fibulin-1, FBLN1）作为血清标志物在结肠直肠癌（colorectal cancer, CRC）诊断中的价值。 方法：选取81例CRC患者作为CRC组,50例结肠直肠息肉患者（息肉组）和50名健康体检者（健康组）作为对照,采用酶联免疫吸附试验（enzyme-linked immunosorbent assay, ELISA）检测其血清FBLN1及癌胚抗原（carcinoembryonic antigen,CEA）水平,并进行组间比较分析。 结果：与血清CEA类似,CRC组的血清FBLN1水平[（12.98±7.82） ng/mL]明显高于息肉组[（7.54±1.23） ng/mL]和健康组[（6.89±2.03） ng/mL],差异均具有统计学意义（P<0.05）,息肉组与健康组间的血清FBLN1水平差异无统计学意义。低分化CRC患者的血清FBLN1水平[（22.23±18.51） ng/mL]分别高于中分化CRC[（11.65±13.28） ng/mL,P<0.05]及高分化CRC患者[（9.12±10.17） ng/mL,P<0.05],有淋巴结转移的CRC患者的血清FBLN1水平[（15.26±6.98） ng/mL]高于无淋巴结转移的患者[（8.58±4.27） ng/mL,P<0.05]。血清FBLN1>9.85 ng/mL诊断CRC的受试者操作特征（receiver operating characteristc,ROC）曲线下面积为0.852,灵敏度为82.7%,特异度约为90.0%,均优于CEA（灵敏度64.2%,特异度为82.1%）。 结论：血清FBLN1水平有可能作为CRC诊断及判断病理分化程度、淋巴结转移情况的标志物。

Objective: To investigate the performance of serum fibulin-1 (FBLN1) detection in diagnosis and prognosis prediction of colorectal cancer. Methods: A total of 81 patients with colorectal cancer(CRC group), 50 patients with benign colorectal polyps (polyps group) and 50 healthy individuals (healthy group) were enrolled. Serum levels of FBLN1 were detected by enzyme-linked immunosorbent assay(ELISA), CEA was also measured, and difference between groups was analyzed. Results: Similar to serum CEA, serum levels of FBLN1 were significantly higher in patients with colorectal cancer [(12.98±7.82) ng/mL] than in patients with benign colorectal polyps [(7.54±1.23) ng/mL] (P<0.05) and healthy individuals [(6.89±2.03) ng/mL] (P<0.05), respectively. No significant difference were found in FBLN1 level between patients with benign colorectal polyps and healthy individuals. The serum level of FBLN1 in patients with low differentiated CRC[ (22.23±18.51) ng/mL] was higher than that in patients with medium differentiated CRC [(11.65±13.28) ng/mL] (P<0.05) and patients with high differentiated CRC[(9.12±10.17) ng/mL] (P<0.05), respectively. The serum level of FBLN1 in CRC patients with lymph node metastasis[(15.26±6.98) ng/mL] was higher than that in patients with no lymph node metastasis [(8.58±4.27) ng/mL (P<0.05). The detection of FBLN1 for diagnosing CRC had a greater AUC(0.852) than CEA,with sensitivity of 82.7% and specificity of 90.0%. Conclusions: Serum FBLN1 can serve as a biomarker for diagnosis and prognosis prediction of CRC.